Florida-Based Team Gemini Signs Recycling Facility Agreement with…

Synergistic relationship between both companies will build an innovative waste recycling facility and reduce landfills using waste-to-energy conversion technologies(PRWeb January 08, 2013)Read the full story at http://www.prweb.com/releases/team-gem…



Opedix® Joint Support Compression Apparel Unveils New CORE-Tec™…

Ideally suited for athletic training, recovery, and participating in physical activities, CORE-Tec shorts, the latest innovation from the Opedix joint support compression apparel line, are designed to…(PRWeb January 08, 2013)Read the full story at…



Cieri Media Announces New Science Series 'Bright Ideas'…

Science as discovery offers a way of learning how things work today, in the past, and in the future. Bright Ideas will explore the cutting edge of science and inventions, looking for the innovator…(PRWeb January 08, 2013)Read the full story at htt…



Cieri Media Announces New Science Series ‘Bright Ideas’…

Science as discovery offers a way of learning how things work today, in the past, and in the future. Bright Ideas will explore the cutting edge of science and inventions, looking for the innovator…(PRWeb January 08, 2013)Read the full story at htt…



Drug Patent Expirations for Dec 26 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations


ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate Plan Premium
Plan
Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for December 26 2012

Tradename Applicant Generic Name Patent
Expiration
SPIRIVA Boehringer Ingelheim tiotropium bromide monohydrate Dec 26, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.



Continue reading

Call for papers: Journal of Commercial Biotechnology

The April  issue of the Journal of Commercial Biotechnology will be distributed for free at BIO 2013 in Chicago this spring. This free, expanded, distribution is a great opportunity for authors and advertisers. The Journal of Commercial Biotechnology, in print since 1994, is the definitive international quarterly publication for bioscience business professionals. The Journal is designed specifically for […]



Journal of Commercial Biotechnology Vol 19, Issue 1 (2013)

The other side of innovation Peter J. Pitts Government sponsored comparative effectiveness research is the first step towards allowing Uncle Sam to push a restrictive formulary on more and more Americans – with step one in the process being unfettered (and unregulated) communications efforts. Unless we are aware and vigilant, such cost-think may very well […]



Drug Patent Expirations for Dec 19 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations


ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate Plan Premium
Plan
Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for December 19 2012

Tradename Applicant Generic Name Patent
Expiration
TASMAR Valeant Pharms Llc tolcapone Dec 19, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Share this:


Continue reading

Drug Patent Expirations for Dec 25 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations


ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate Plan Premium
Plan
Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for December 25 2012

Tradename Applicant Generic Name Patent
Expiration
ASMANEX TWISTHALER Schering mometasone furoate Dec 25, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.



Continue reading